[
    {
        "molecule_name": "Example 80",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.040",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 390",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.017",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 110",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.174",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 110",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.040",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 313",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.037",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 515",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.491",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 70",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.055",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 118",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.023",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 119",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.014",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 121",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.036",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 139",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.207",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 540",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.121",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 710",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.004",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 427",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "20",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 773",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.014",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 374",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.009",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 812",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "173.18",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 80",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.028",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 120",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.057",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 140",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.251",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 60",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.142",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 00",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.043",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    },
    {
        "molecule_name": "Example 390",
        "protein_target_name": "5-HT<sub>6</sub> Agonist Site",
        "binding_metric": "Ki",
        "value": "0.275",
        "unit": "μM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n\nFor these membranes a K<sub>D </sub>of 1.95 nM for [<sup>3</sup>H]-LSD (Lysergic Acid Diethylamide; Amersham, TRK1038) was determined by means of saturation binding experiments.\nIn these tests, the compounds according to the invention exhibit good affinity for the 5-HT<sub>6 </sub>receptor (K<sub>i</sub>&lt;1000 nM or &lt;50 nM).\nTABLE 6\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.040\n390\n0.017\n110\n0.174\n110\n0.040\n313\n0.037\n515\n0.491\n70\n0.055\n118\n0.023\n119\n0.014\n121\n0.036\n139\n0.207\n540\n0.121\n710\n0.004\n427\n20\n0.071\n773\n0.014\n374\n0.009\n812\n173.18\nTABLE 7\n5-HT<sub>6 </sub>Agonist Site Radioligand Binding\nExample\nKi (μM)\n80\n0.028\n120\n0.057\n140\n0.251\n60\n0.142\n00\n0.043\n390\n0.275"
    }
]